Monopoly is a lever chains pull when guest counts are soft, so it signals a squeezed consumer, not a particular point in the macro cycle.
The 2026 numbers fit that read. In Q2 2026, U.S. comparable sales rose only 0.8%, driven by higher check sizes while guest counts fell. The stock was near a two-year low in September, well below its all-time high of $334.50 from February 2026.

So if Monopoly is an indicator at all, it doesn't say "recession." It says consumers have stopped absorbing price hikes, which tends to happen in the late stage of a cycle, after inflation has squeezed budgets.

Timeline of lineup.

1987 launch: This came right after the Black Monday crash, late in the 80s expansion, during the "burger wars" with Burger King and Wendy's. Competition for traffic was fierce, so a game made sense.
Late 80s through 2001: The game ran almost every year through the 1990–91 recession and the long 90s boom. It was mostly marketing, not a cycle signal.
2001 pause: The FBI exposed the "McMillions" fraud in August 2001, the same year as the dot-com recession. That timing is coincidence; the scandal killed the game, not the economy.
Early 2000s return through 2016: It came back during the post-2001 recovery and kept running straight through the 2008–09 crisis. That fits the "trade down" story, since people swapped sit-down restaurants for fast food and promos helped capture them.
2017–2024 hiatus: This is the most telling stretch. First came a strong late-2010s economy, then the pandemic and inflation years, when McDonald's raised prices aggressively and customers still showed up. When you can raise menu prices freely, you don't need to give away Jeeps.
2025–26 return: It came back once the "$18 Big Mac meal" backlash and the pullback by lower-income customers ended that pricing power.

The question for Axon Enterprise is no longer whether the Flock Safety backlash will impact the business, but how severe that impact will be. Flock currently faces mounting privacy scrutiny, with councils canceling contracts, governors restricting highway deployments, and new data-retention rules being drafted. Because Axon competes directly in this space, the risk is real. However, the magnitude is what matters, and that is what this analysis quantifies.

Most DCFs model Axon top-down, applying a single revenue line and a blended margin assumption. However, Axon is effectively five distinct businesses, each scaling at a different rate with its own margin profile. Because Axon officially reports only two operating segments, the five-way split relies on extrapolating product-level disclosures from earnings calls and investor days. I built this model bottom-up, with five segments over eleven years (2026-2036), each carrying a dedicated revenue, EBITDA, and FCF bridge. Deriving standalone margins from this data inherently requires judgment, making it a valid source of estimation error worth flagging.

The five segments by 2026 to 2036 revenue are as follows.

* Evidence.com / Cloud SaaS: $1.6B → $18.5B. This represents 43% of the business today, scaling to 63% by 2036. The EBITDA margin expands from 32% to 42.5%. This is the core compounder.
* TASER: $900M → $4.0B. A classic razor-and-blades model, with EBITDA margins scaling from 28% to 32.5%.
* Dedrone (counter-drone): $450M → $3.47B. This is the highest growth segment, expanding 30% annually through 2030. EBITDA scales from 12% to 32.5%, representing the steepest margin ramp in the portfolio.
* Bodycams / Sensors: $575M → $2.3B. A mature, replacement-cycle business that primarily serves to feed the Evidence.com flywheel.
* ALPR / RTCC / Fusus: $175M → $1.28B. This is where the Flock backlash lands, representing under 5% of total 2036 revenue.

Total revenue goes from $3.7B to $29.5B, generating $11.2B in EBITDA (37.8% margin) and $7.2B in unlevered FCF by 2036.

On quantifying the backlash, the direct revenue at risk is relatively small. The more critical dynamic is the cross-selling impact, which is where the primary risk lies. The $732M hit captures ecosystem effects well beyond direct ALPR revenue, since slower fixed-sensor deployments inherently make drones, Evidence.com, and Fusus incrementally less valuable.

Regarding the valuation bridge, at the SOTP's 24.5% terminal FCF margin, $732M in revenue translates to roughly $179M in annual terminal free cash flow. Capitalized as a growing perpetuity and discounted back at the model's WACC, that equates to $8 to $9 per share in present value, about 1.4% of the $609.50 base target. Because this is a 2036 figure being discounted over a decade, the actual impact in present value terms is smaller than the 2.4% headline revenue hit suggests. It is a real, quantifiable impact, but it does not alter the broader investment case. It simply creates a more attractive entry point.

The valuation works out to Bear $288.89, Base $609.50, Bull $779.28, with a Buy rating.

The key risks to the thesis start with privacy restrictions broadening from ALPR to drones, or beginning to impair renewal economics on the Evidence.com installed base. In that scenario the damage would compound significantly, and my $288.89 bear case is explicitly calibrated to it.

This near-term versus long-term tension is crucial. Flock's current troubles serve as a vendor-consolidation tailwind for Axon, as municipalities switch providers. The model treats this as a near-term share gain nested within a broader, long-term ecosystem risk. If Flock resolves its privacy issues and reaccelerates, that tailwind will fade. Other key risks include Evidence.com net revenue retention dropping below 110%, or integration stumbles with the Dedrone acquisition.

1. DCF is not a magic tool.

I know you guys love DCF, but I’m going to push back.

As you know, DCF is very sensitive to assumptions.

In other words, it is a method applicable to companies where reasonable assumptions can be made.

You should use it for companies where you can reasonably estimate revenue, margin, and CAPEX.

But this company is not suitable for DCF.

For DCF use, some accounting items need to be classified subjectively.

You need to sort them after reading the disclosure, but since you are just mechanically entering data into Excel, of course, the calculations are wrong.

If you look at Damodaran’s blog, he explains how he classifies items for each company, but that doesn’t seem to be the case with you guys.

I think you already know that many items of FCF, WACC, and the EV-to-equity bridge require interpretation.

Issues related to future forecasting, such as growth rates, will be explained below.

2. Applovin's performance cannot be predicted.

Whether using DCF or rough estimates, predictability is a prerequisite.

Do you have a tool to estimate Applovin's revenue and EBITDA?,

Is there anyone who can track and investigate the entire industry with precision?

Of course not.

If there is no predictability, you have no choice but to rely on guidance, and consensus must also depend on guidance.

I do not deny that Applovin's business model itself is excellent, but whether the model is predictable is a different matter.

Only part of the customer composition is available in the disclosure; no one knows how the take-rate will change, whether the stagnation in the number of customers will be resolved, or how much revenue per customer will keep growing.

Since it’s unpredictable, there’s no action to take other than waiting for earnings releases. To understand this company’s stock price, all you need to do is look at next quarter’s earnings release.

This is not a problem that can be resolved unless the company monopolizes the entire market and becomes the market itself.

As a result, long-term capital has thinned out while short-term money has grown, so the stock has shown high beta for years.

The approach of naively solving it by using the DCF is flawed.

3. Holding Period

It may sound obvious, but the returns vary depending on how many years you plan to hold.

From a long-term holding perspective, there are several ways to have grounds for being confident that growth will continue as it stands.

- As an industry insider, if you can sense the potential of applovin

- When you know the management very well

- When you have access to insider materials or have access to confidential materials

In these cases, it can be a well-founded investment.

Otherwise, it isn’t.

Ironically, “I roughly compared it to comps” is a better-grounded basis than a DCF.

I wish you would stop glazing DCF, read the disclosures, and start talking about business first.

TL;DR

Garbage in, garbage out.

When 80% of your valuation is terminal value on a company you can’t forecast two quarters out, you’re not doing valuation. You’re writing fan fiction with a discount rate.

Better to be roughly right than precisely wrong.

At about $70, Netflix’s price needs roughly 9% yearly free cash flow growth for 10 years. That’s well below its recent pace, which makes the margin of safety bigger than I expected. But the headline P/E is distorted by a one-off, so the details matter. Netflix reports Tuesday.

Step 1: Quality (is this a business worth owning?)

• Growth: revenue grew 16% in 2025 and is guided to +12-14% in 2026
• Margins: operating margin 26.7% (2024), 29.5% (2025), 31.5% guided for 2026
• Cash: free cash flow $6.9B (2024), $9.5B (2025), ~$11B guided for 2026
• Balance sheet: about $14.3B of debt against $9.1B of cash, so net debt is around $5B, roughly half a year of free cash flow
• Buybacks: ~$6B in the first half of 2026
• Moat: scale. Per Hudson Labs, 325M+ paid members and under half of addressable households reached

Netflix’s free cash flow is after roughly $20B a year of cash content spend. Content works like capex here, so I treat the cash number as the honest one, not operating income.

Step 2: Price, via a reverse DCF

Instead of asking “what’s it worth?”, I ask what growth today’s price requires. At ~$70 (Oct 14 close) and ~4.26B diluted shares, the market cap is about $300B and enterprise value about $306B. Starting from ~$11B of 2026 free cash flow, with 3% terminal growth, here’s the 10-year growth the price requires:

And going the other way, the value per share at a 9% discount rate:

Free cash flow has grown much faster recently (+38% in 2025, ~+16% guided for 2026), so the price asks for a sharp slowdown, to about 9%. That doesn’t make it a bargain automatically, but there’s room for things to go a bit wrong.

The P/E trap

Netflix’s 2026 estimated EPS looks like ~$3.58, which gives a headline P/E of ~20x. But Q1 includes a $2.8B termination fee from the failed Warner Bros. deal, booked as other income. Strip it out and the P/E is closer to 23x. It’s a good example of why I check what’s inside the earnings number before trusting a multiple.

Risks

• Engagement: viewing hours grew only ~2% in H1 2026
• Content and live-sports costs rising
• The ad business has to deliver on a roughly $3B target
• Restructuring costs from the job cuts
• The ~$11B guide: one source cites ~$12.5B, so check the latest. At $12.5B the implied growth falls to ~7.6%

Q3 guidance was about $12.9B revenue and a 33.2% operating margin. I’d care more about the margin and the 2026 free cash flow guide than the revenue beat, because those drive the cash flow the whole valuation rests on.

Li Lu discusses many broad topics, including the differences of AI versus past technological revolutions, the current market environment, the current Chinese economy, and the evolution of the global world order.

Overall he expects the next few years will have very rich opportunities for “rational investors” because so many are not behaving rationally.

LENZ has about $220M of cash and securities against 31.4M shares, so roughly $7 a share, and no debt. It also burns more than a dollar a share every quarter selling one product, VIZZ, a cash-pay presbyopia eye drop at about $67 net per pack. Most of the bull case stops at the cash number. I don't think the cash is the interesting part.

The interesting part is retention. The company talks about a 42% repurchase rate and "five boxes a year," but those are model figures from an auto-refill ePharmacy. The first real cohort with a patient denominator came out at ESCRS in October: 61 patients, three months, 9 still using the drop. That is 14.8%, with about 40% reporting bothersome side effects (dim vision, headache), which come from the pharmacology, not the packaging.

Demand is a different story. Google Trends for "VIZZ eye drops" shows four advertising waves since July, each peak higher than the last and the current one the highest since launch. Between waves the index falls back to zero. Pack volume went 23.5K, 25K, 27K over the last three quarters. My estimate from the Trends data is that Q3 ad spend ran around $25M, and the fourth wave is still running into the Q3 report.

So who stops the spending? Management dropped its "cash to profitability" language in Q2, RA Capital's partner left the board in June, Fidelity went from 15% to under 6%, and the ATM is used up. Lease liabilities are under $1M and ad contracts can stop month to month, so a quick stop is possible. Nothing in the record says it is being considered.

The honest counterpoint: the real-world safety data is clean, the CEO has sold a company before, and a Q3 print with packs near 50K plus a real retention curve would change my mind quickly.

Full writeup with the probability-weighted math, charts and sources: https://latenttensorcapital.com/p/lenz-therapeutics-lenz-who-decides

Not investment advice. I may hold positions in securities mentioned.

Anyone invested in CATL? Stock is down massively over the past few weeks, but I hear nothing but good things about their batteries.

They own some of the mines for precious metals, and are at the forefront in R&D, in a growing market, so why is the stock dropping?